Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01193140 · ClinicalTrials.gov registry record · Phase 2
To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors
A Phase 2 study of Solid Tumor Cancers, sponsored by Abbott.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT01193140: Completed Phase 2 study of Solid Tumor Cancers, sponsored by Abbott.
NCT01193140 is a Phase 2 study of Solid Tumor Cancers that has completed, run by Abbott. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01193140, a Phase 2 study of Solid Tumor Cancers, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
To evaluate the safety and tolerability of the veliparib/TMZ combination in subjects with solid tumors.
Primary Outcome
Safety and tolerability will be assessed through clinical laboratory tests, electrocardiograms (ECGs), vital signs, physical exams and adverse event assessments
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG veliparib
Study Locations (2)
California
- Site Reference ID/Investigator# 43022 - Encinitas
- Site Reference ID/Investigator# 42662 - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
What the finished NCT01193140 record still lists
NCT01193140 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Solid Tumor Cancers appearing as the primary indexed condition, and to 2 interventions - of which Temozolomide is the first listed.
NCT01193140 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01193140 about?
NCT01193140 is a clinical study titled "To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors". To evaluate the safety and tolerability of the veliparib/TMZ combination in subjects with solid tumors.
What is the current status of trial NCT01193140?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2010-07. Estimated completion is 2011-11.
What conditions does trial NCT01193140 study?
This clinical trial studies the following conditions: Solid Tumor Cancers.
What interventions are being tested in trial NCT01193140?
The interventions under investigation include: Temozolomide (DRUG), veliparib (DRUG).
Who is sponsoring clinical trial NCT01193140?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01193140 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01193140's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia